Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Kinetics of protective antibodies are determined by the viral surface antigen
Daniel D. Pinschewer, … , Juan Carlos de la Torre, Rolf M. Zinkernagel
Daniel D. Pinschewer, … , Juan Carlos de la Torre, Rolf M. Zinkernagel
Published October 1, 2004
Citation Information: J Clin Invest. 2004;114(7):988-993. https://doi.org/10.1172/JCI22374.
View: Text | PDF
Article Infectious disease

Kinetics of protective antibodies are determined by the viral surface antigen

  • Text
  • PDF
Abstract

Delayed and weak virus neutralizing antibody (nAb) responses represent a hallmark correlating not only with the establishment of persistent infection but also with unsuccessful vaccine development. Using a reverse genetic approach, we evaluated possible underlying mechanisms in 2 widely studied viral infection models. Swapping the glycoproteins (GPs) of lymphocytic choriomeningitis virus (LCMV, naturally persisting, noncytolytic, inefficient nAb inducer) and vesicular stomatitis virus (VSV, nonpersisting, cytolytic, potent nAb inducer) transferred the only target of nAb’s from either virus to the other. We analyzed the nAb response to each of the 2 recombinant and parent viruses in infected mice and found that nAb kinetics were solely determined by the viral surface GP and not by the virus backbone. Moreover, the slowly and poorly nAb-triggering LCMV virion was a potent immunogenic matrix for the more antigenic VSV-GP. These findings indicate that the viral GP determines nAb kinetics largely independently of the specific viral infection context. They further suggest that structural features of viral GPs or coevolutionary adaptation of the virus’s GP to the host’s naive B cell repertoire, or both, may critically limit nAb kinetics and improvement of vaccine efficacy.

Authors

Daniel D. Pinschewer, Mar Perez, Eswaraka Jeetendra, Thomas Bächi, Edit Horvath, Hans Hengartner, Michael A. Whitt, Juan Carlos de la Torre, Rolf M. Zinkernagel

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Protective capacity of the rLCMV/INDG-induced nAb response. A129 mice we...
Protective capacity of the rLCMV/INDG-induced nAb response. A129 mice were immunized on day 14 prior to challenge with live rLCMV/INDG (right bar in A, squares in B) or rLCMV/NJG (center bar in A, inverted triangles in B), or were left uninfected (left bar in A, diamonds in B). (A) On day 0, serum samples were tested for VSV-IND_neutralizing IgG, and all mice were challenged i.v. with 5 × 106 PFU VSV-IND. (B) Daily monitoring for clinical signs of terminal myeloencephalitis. Symbols represent the mean of 3 mice per group ± SD. One representative experiment of 2 similar experiments is shown.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts